Israeli HealthTech Startup UltraSight Raises $24 Million in Series B2 Funding
UltraSight, an Israeli startup based in Rehovot, has announced the successful completion of a $24 million Series B2 funding round. The company develops an AI-powered platform for echocardiography workflows. The investment was led by Alive HealthTech Growth Fund and included participation from Deep Insight, Star51 Capital, Connecticut Innovations, and eHealth Ventures, as well as existing investors like Mayo Clinic Ventures, NYU, and Iron Nation.
This latest funding brings UltraSight's total capital raised since its inception in 2018 to $42 million. The funds will be used to expand the company's commercial operations and implementation within U.S. healthcare systems. Additionally, the capital will support the development of new clinical applications for intensive care units, where rapid cardiac imaging is crucial for treatment decisions.
UltraSight was founded by Itai Kazorer (CTO), Yaron Lifman (Scientific Advisor), and Ahi Lodmersky (Chief Medical Officer), with Davidi Vortman serving as CEO. The company currently employs 25 people, with 19 based in Israel and the rest in the U.S. UltraSight operates in the echo-cardiography market, which faces challenges due to increasing demand for cardiac tests and a shortage of skilled sonographers, leading to bottlenecks and delays in clinical decision-making.
The company's platform, UltraSight Echosystem, aims to address this by combining structured training with real-time AI guidance. This enables medical staff, who are not necessarily expert sonographers but have received appropriate training, to perform focused point-of-care echo tests under the supervision of a qualified physician. This approach helps hospitals improve patient flow, reduce wait times, and optimize medical staffing.
UltraSight's development is supported by strong clinical validation, including FDA clearance (K510) and recent studies published in JAMA Cardiology, demonstrating the system's accuracy in identifying various clinical conditions. The UltraSight Echosystem is currently installed in over 10 leading commercial medical sites in intensive care units, integrating into clinical workflows to overcome challenges in cardiac imaging.
Recently, TIME magazine recognized UltraSight as one of the world's leading HealthTech companies in its TIME World's Top HealthTech Companies 2026 ranking. CEO Davidi Vortman stated that the funding will help expand market adoption, deepen strategic collaborations, and increase access to quality cardiac ultrasound, ultimately reducing treatment times for patients. Dudi Klein, Managing Partner at Alive, noted that UltraSight combines clinical evidence with a scalable business model in a market with workforce shortages and access barriers. Rick Jelliff, who recently joined as Chairman of the Board, brings over 30 years of experience in the cardiovascular device industry and highlighted the company's potential to address the long-standing need for advanced cardiac imaging solutions independent of a limited number of specialists.